What is Leerink Partnrs’ Estimate for AURA FY2025 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Stock analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Aura Biosciences in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($1.98) per share for the year, down from their prior estimate of ($1.93). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ FY2026 earnings at ($2.27) EPS.

A number of other equities analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. BTIG Research increased their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, Scotiabank raised their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Down 0.5 %

Shares of Aura Biosciences stock opened at $7.76 on Monday. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38. The firm has a market cap of $387.61 million, a PE ratio of -4.49 and a beta of 0.29. The business has a 50-day moving average price of $8.17 and a 200 day moving average price of $8.86.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its position in shares of Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Aura Biosciences in the third quarter valued at $169,000. Charles Schwab Investment Management Inc. boosted its position in Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after acquiring an additional 3,612 shares during the period. State Street Corp boosted its holdings in shares of Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares during the period. Finally, Wellington Management Group LLP purchased a new position in shares of Aura Biosciences during the 3rd quarter valued at $1,037,000. 96.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Aura Biosciences

In other news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,778 shares of company stock valued at $240,706. 5.40% of the stock is owned by insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.